Scarica l'app Stockscreener
0.00
100.00%
-115.07
Dopo l'orario di chiusura:
115.11
115.11
+
Precedente Chiudi:
$115.07
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$6.73B
Reddito:
$22.29M
Utile/perdita netta:
$-228.93M
Rapporto P/E:
0.00
EPS:
-4.0547
Flusso di cassa netto:
$-212.59M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$115.13
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
0.00 | 6.73B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-22 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
OpGen Inc. (OPGN) Peer Comparison – Compare with Others - valueresearchonline.com
Arcellx (ACLX) Latest Quarter: The Available Earnings Metric Delivers a Beat in Latest Trading ; Trading Response Is Still PendingBook Value Growth - vinanet.vn
Arcellx (ACLX) Latest Quarter: EPS Exceeds Its Estimate ; Results Are Reported Without a Trading SignalPositive Surprise Momentum - vinanet.vn
7 biopharma M&A deals where layoffs followed - BioSpace
ACLX Q4 2025 Earnings: Narrower-Than-Expected Loss Reflects Clinical-Stage DisciplineProfit Margin Analysis - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineRevenue Guidance Update - vinanet.vn
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - stocktwits.com
Arcellx (ACLX): Paradigm BioCapital group files 13G/A showing 0% stake - Stock Titan
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss of $1.01 Per Share Underscores Clinical-Stage Focus - vinanet.vn
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Former Arcellx CFO Joins Rani Therapeutics Board After Gilead Acquisition - Stock Titan
Arcellx Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Continued Operational DisciplineBasic EPS Analysis - vinanet.vn
Gilead extends Arcellx tender offer again - MSN
Arcellx (ACLX) Holds Steady as Biotech Stock Consolidates Near SupportSector Sentiment - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Drives Modest Stock GainAnalyst Consensus Shift - vinanet.vn
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - The National Law Review
Arcellx (ACLX) Stock Analysis: Why Arcellx (ACLX) Is Stuck at $115.07 2026-07-09Dollar Neutral Pair - dars.gov.et
Arcellx Inc. (ACLX) Holds Near Key Support Amidst ConsolidationBuyback Factor - DonanımHaber
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss, Flat Stock ReactionPost-Earnings Reaction - dars.gov.et
Arcellx (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Guidance Update - dars.gov.et
How Arcellx Inc. (ACLX) Affects Rotational Strategy Timing - Stock Traders Daily
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
ACLX Q4 2025 Earnings: Effective Cost Management Leads to Narrower-Than-Expected LossNet Income Trends - dars.gov.et
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss on Operational EfficiencyNext Quarter Guidance - dars.gov.et
Arcellx (ACLX) Holds Near $115 as Biotech Stock Consolidates in Narrow RangeDynamic Hedging - DonanımHaber
Arcellx Inc (ACLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcellx Inc (ACLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcellx Inc (ACLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcellx Inc (ACLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arcellx Inc. (ACLX) Holds Near Support as Consolidation ContinuesFast Moving Stocks - newsline.com
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineGuidance Update - newsline.com
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Arcellx Inc. (ACLX) Consolidates Near Key Support Level as Biotech Sector Awaits CatalystsPrice Gap Fill - newsline.com
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals ProgressWeak Earnings Momentum - dars.gov.et
Arcellx (ACLX) Holds Steady Near $115 as Support and Resistance Levels Define Trading RangegetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx (ACLX) Holds Steady Near Support Amid Biotech Sector VolatilitygetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
ARCELLX Q1 2026 Earnings Preview: Recent $ACLX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Arcellx (ACLX) Amendment shows Vestal Point and Wilder report 0% ownership - Stock Titan
[15-12G] Arcellx, Inc. SEC Filing - Stock Titan
Gilead wipes out most of Arcellx workforce - BioSpace
7 months after last layoffs, Bay Area biotech giant does another round - SFGATE
Bay Area biotech takes another hit as Gilead announces major job cuts - Yahoo Finance
Gilead to lay off dozens in Rockville after closing Arcellx acquisition - The Business Journals
Rutgers axes graduation speaker after anti-Israel social media posts allegedly drew student backlash - New York Post
MSN Money - MSN
Gilead to lay off nearly 200 workers after Arcellx acquisition closes - The Business Journals
Bay Area biotech giant Gilead to lay off 108 workers in Redwood City - San Francisco Chronicle
Gilead completes Arcellx buy, securing myeloma treatment anito-cel - Rare Cancer News
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):